SENTIS™ Cancer+ Discovery Testing

Introduction

SENTIS™ Cancer+ Discovery Testing provides your labs with one of the market’s most comprehensive and accurate NGS-based testing solution for the identification of actionable somatic and germline mutations and the discovery of novel variants with important functions in cancer. The panel offers 816 cancer-related genes and interrogates the most common types of alterations, including SNVs, indels, CNVs and fusions in solid tumors, which provides comprehensive medication guidance on targeted therapy, chemotherapy, and immunotherapy for patients with solid tumors, as well as hereditary tumor risk assessment, to comprehensively assist patients in finding treatment options that may be of benefit.

What clinical challenges are targeted by SENTIS™ Cancer+ Discovery Testing

Traditional tumor companion diagnostic detection methods mainly include PCR, IHC, FISH. Although PCR can detect gene hotspots in a short time and has high sensitivity and specificity, its throughput are limited. It can only be used to detect common hotspot mutations related to targeted therapy, which is easy to miss some variants and cannot discover new mutations.

FISH can only detect a small number of copy number mutations and cannot discover new fusions.

IHC only detects biomaker related to protein levels, with limited evidence for drug use and relatively single targets. With the approval of more and more pan-cancer solid tumor Biomakers, there is an increasing need for comprehensive gene detection products that can cover hundreds or thousands of genes in one test.

Applicable Clinical Scenarios

Patients with solid tumor in early and mid-stage before neoadjuvant therapy

Patients with solid tumor in early and mid-stage before adjuvant therapy

Patients with solid tumor in advanced stage before first-line treatment

Patients with solid tumor in advanced who need to find the cause of drug resistance and adjust their treatment plan after drug resistance

Important features of SENTIS™ Cancer+ Discovery Testing

Gene numbers	816 genes
Panel size	1.89Mb
Variants type	SNV, Indel, CNV, fusion
Cancer type	Solid tumor^✱
LOD	LOD: 1%(tissue), 0.5% (ctDNA)
Sequencing depth	1200X(Tissue), ≥2700X (ctDNA)
Genes and drugs	360+ tumor drugs, 285 genes related to targeted therapy, covering tumor mutation load (TMB) microsatellite instability (MSI), 32 genes related to immune checkpoint inhibitors therapy, 72 genes related to hereditary cancer risk assessment, and 74 genes related to HRR
Sample type	Fresh tissue/Biopsy tissue/paraffin section/DNA (excluding bone sample type), peripheral blood (control)